Japan Pricing Update: Trodelvy, Tepezza Win Usefulness Premiums, Awiqli Struggles
Multiple New Drugs Price-Listed In NHI
While Japan awarded relatively high premiums to several products newly listed for reimbursement, others were the subject of prolonged debate or are facing imminent cost-effectiveness assessment.